Hutchison Pharmaceuticals rose nearly 10%. As of press release, it rose 9.76% to HK$24.75, with a turnover of HK$0.2 billion.

According to the news, Hehuang Pharmaceutical announced that the new drug marketing application for patients with ORPATHYS (ORPATHYS, savolitinib) and TARISSA (TAGRISSO, osimertinib) (TAGRISSO, osimertinib) for treating EGFR mutation-positive disease progression after receiving first-line epidermal growth factor receptor (EGFR) inhibitors with MET amplification has been accepted and prioritized by the China National Drug Administration. Warisal is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI). Teresa is an irreversible third-generation EGFR TKI. This acceptance will also trigger a milestone payment from AstraZeneca.

According to reports, the combination therapy of Warissa and Teresa was included by the State Drug Administration as a breakthrough treatment for this potential indication in December 2024. The State Drug Administration included this combination therapy as a breakthrough treatment and approved it as a new treatment for serious diseases. Clinical evidence shows clear advantages over existing treatment methods.

Edit/Rocky